Medicine and Dentistry
Patient
74%
Analysis
50%
Actinic Keratosis
43%
Mycosis fungoides
43%
Chemotherapeutic Agent
43%
Drug
43%
Apremilast
43%
Prevalence
43%
Dermatology
43%
Outpatient
43%
Survival
43%
Kidney Transplantation
43%
Psoriasis
43%
Predictor
43%
Solid Organ Transplantation
21%
Diseases
21%
Psoriasis Area and Severity Index
19%
Inpatient
14%
Therapeutic Procedure
14%
Skin
12%
Screening
9%
Squamous Cell Carcinoma
9%
Age
9%
Gamma Delta T-Cell
7%
Bone Marrow Biopsy
7%
Electron Therapy
7%
Contraindication
7%
Lymph Duct
7%
Neoplasm
7%
Immunosuppressive Treatment
7%
Immunosuppressive Drug
7%
T Cell
7%
Biopsy
7%
Diagnosis
7%
Enalapril Maleate
7%
Comprehension
7%
Chemotherapy
7%
Organ
7%
Pharmacology, Toxicology and Pharmaceutical Science
Psoriasis
100%
Drug
94%
Biological Product
91%
Survival
65%
Survival Rate
48%
Apremilast
43%
Interleukin 17 Antibody
43%
Interleukin 23 Antibody
43%
Interleukin 23p19
19%
Ixekizumab
13%
Ustekinumab
13%
Secukinumab
13%
Interleukin 23
11%
Diseases
9%
Etanercept
8%
Psoriatic Arthritis
8%
Adalimumab
8%
Cohort Study
8%
Adverse Event
7%
Nursing and Health Professions
Drug
86%
Analysis
86%
Survival
65%
Psoriasis
52%
Survival Rate
48%
Biological Product
43%
Apremilast
43%
Time
43%
Interleukin 17 Antibody
43%
Psoriasis Area and Severity Index
23%
Secukinumab
13%
Ixekizumab
13%
Ustekinumab
13%
Diseases
9%
Hazard Ratio
9%
Patient
8%
Psoriatic Arthritis
8%
Adalimumab
8%
Etanercept
8%
Gender
8%
